Angiomotin Protein Newly Linked to Initial Tumor Growth in Several Cancers

A team led by scientists from The Scripps Research Institute (TSRI) has shown that a protein once thought to inhibit the growth of tumors is instead required for initial tumor growth. The findings could point to a new approach to cancer treatment. The study was published as the cover article of the September 3, 2013 issue of the journal Science Signaling. The focus of the study was angiomotin, a protein that coordinates cell migration, especially during the start of new blood vessel growth and proliferation of other cell types. “We were the first to describe angiomotin’s involvement in cancer,” said Dr. Joseph Kissil, a TSRI associate professor who led the studies. “ And while some following studies found it to be inhibiting, we wanted to clarify its role by using both cell studies and animal models. As a result, we have now found that it is not an inhibitor at all, but instead is required for Yap to produce new tumor growth.” Yap (yes-associated-protein) is a potent oncogene that is over-expressed in several types of tumors. In addition to identifying angiomotin’s critical role in tumor formation, Dr. Kissil and his colleagues found the protein is active within the cell nucleus. Earlier cell studies focused on the function of the protein at the cell membrane. “This pathway, which was discovered less than a decade ago, appears to regulate processes that are closely linked to cancer,” Dr. Kissil said. “The more we study it, the more we see its involvement.” The first authors of the study are Dr. Chunling Yi of Georgetown University Medical Center and Dr. Zhewei Shen of the University of Pennsylvania. Other authors include Dr. Anat Stemmer-Rachamimov of Massachusetts General Hospital; Drs. Noor Dawany, Louise C. Showe and Qin Liu of The Wistar Institute; Dr. Scott Troutman of TSRI; Dr. Akihiko Shimono of TransGenic, Inc.; Dr.